Medical Economics overhauls editorial team

Share this article:

Advanstar's Medical Economics title announced the hiring of five new senior-level editors.  The new editorial team is located in Cleveland, Ohio. The magazine was formerly headquartered in Woodcliff Lake, NJ.

New editorial staff at Medical Economics is as follows:

• Erich Burnett, editor in chief
• Ken Krizner, managing editor
• Bob Feigenbaum, articles editor
• Brandon Glenn, senior editor
• Morgan Lewis Jr., senior editor

The announcement follows a merging of several Advanstar titles – including Medical Economics – into the Healthcare Centralized Content Group last April. Drug Topics, Formulary, Managed Healthcare Executive, and Geriatrics are also included in the group. The Healthcare Centralized Content Group delivers customized content from the aforementioned titles through print, multimedia and e-media platforms.

The new editorial team at Medical Economics will report to Tara Stultz, executive editorial director, Primary Care and Healthcare Centralized Content Group, according to a statement. Burnett, the new editor in chief, worked for 12 years at Village Voice Media, before his appointment at Medical Economics.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...